EUVIMEDEUVIMED entdecken
Crossref

Asthenic syndrome in cardiovascular and endocrine diseases. Potential of nutraceuticals in combination therapy

Dmitry I Trukhan, Marina V Moiseeva, Yulia S Kozulina, Yulia S Kozulina, Victoria V Goloshubina, Darya S Ivanova, Innokenty S Chusov, Innokenty S Chusov

Clinical review for general practice · 19.06.2026 · 7 (4) · 79-88

DOI: 10.47407/kr2026.7.4.00826 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical review for general practice, online erschienen am 19.06.2026. Verfasst von Dmitry I Trukhan und 7 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Asthenia/asthenic syndrome is present in the clinical picture of a large number of diseases and conditions, and the causes of asthenia are therefore varied. Vitamin and mineral supplements are an important component in the treatment of post-viral asthenia. The purpose of this review is to examine asthenia/asthenic syndrome in cardiovascular and endocrine diseases and to explore the potential use of vitamins (A, E, C) and trace elements (zinc, selenium) in the combination therapy of these conditions in the presence of asthenic syndrome. Deficiencies of essential antioxidant vitamins (A, E, C) and trace elements (zinc and selenium) are modifiable factors in the development and progression of cardiovascular and endocrine diseases. When choosing a nutraceutical for asthenic syndrome/somatic asthenia associated with cardiovascular and endocrine diseases, current levels of trace elements and vitamins should be taken into account. The use of vitamin and mineral complexes will not only compensate for the energy deficit associated with somatic asthenia associated with cardiovascular and endocrine diseases, but will also not “harm” existing cardiovascular and endocrine pathologies. The data presented in this review demonstrate the advisability of using the trace elements zinc and selenium, as well as vitamins A, C, and E, in the comprehensive treatment of asthenic syndrome/somatic asthenia associated with cardiovascular and endocrine diseases. The availability of Selzinc® nutraceuticals in the arsenal of internists (general practitioners, cardiologists, and endocrinologists) in outpatient care will improve the quality and effectiveness of medical care for patients with cardiovascular and endocrine diseases, including those with the presence and development of somatic asthenia/asthenic syndrome. Keywords: asthenia, asthenic syndrome, post-viral asthenia, somatic asthenia, cardiovascular diseases, thyroid diseases, diabetes mellitus, treatment, nutraceuticals, vitamin A, vitamin C, vitamin E, zinc, selenium.

Zitieren

APA

Trukhan, D. I., Moiseeva, M. V., Kozulina, Y. S., Kozulina, Y. S., Goloshubina, V. V., Ivanova, D. S., Chusov, I. S., & Chusov, I. S. (2026). Asthenic syndrome in cardiovascular and endocrine diseases. Potential of nutraceuticals in combination therapy. Clinical review for general practice, 7(4), 79-88. https://doi.org/10.47407/kr2026.7.4.00826

Vancouver

Trukhan DI, Moiseeva MV, Kozulina YS, Kozulina YS, Goloshubina VV, Ivanova DS, et al. Asthenic syndrome in cardiovascular and endocrine diseases. Potential of nutraceuticals in combination therapy. Clinical review for general practice. 2026;7(4):79-88. doi:10.47407/kr2026.7.4.00826

BibTeX
@article{Trukhan2026,
  author = {Trukhan, Dmitry I and Moiseeva, Marina V and Kozulina, Yulia S and Kozulina, Yulia S and Goloshubina, Victoria V and Ivanova, Darya S and Chusov, Innokenty S and Chusov, Innokenty S},
  title = {Asthenic syndrome in cardiovascular and endocrine diseases. Potential of nutraceuticals in combination therapy},
  journal = {Clinical review for general practice},
  year = {2026},
  volume = {7},
  number = {4},
  pages = {79--88},
  doi = {10.47407/kr2026.7.4.00826}
}
Kostenlos starten →